Dr. Scott M. Glaser
Claim this profileCity of Hope Comprehensive Cancer Center
Affiliated Hospitals
City Of Hope Comprehensive Cancer Center
City Of Hope Medical Center
Clinical Trials Scott M. Glaser is currently running
Apalutamide + Targeted Radiation
for Prostate Cancer
This phase III trial tests two questions by two separate comparisons of therapies. The first question is whether enhanced therapy (apalutamide in combination with abiraterone + prednisone) added to standard of care (prostate radiation therapy and short term androgen deprivation) is more effective compared to standard of care alone in patients with prostate cancer who experience biochemical recurrence (a rise in the blood level of prostate specific antigen \[PSA\] after surgical removal of the prostate cancer). A second question tests treatment in patients with biochemical recurrence who show prostate cancer spreading outside the pelvis (metastasis) by positron emission tomography (PET) imaging. In these patients, the benefit of adding metastasis-directed radiation to enhanced therapy (apalutamide in combination with abiraterone + prednisone) is tested. Diagnostic procedures, such as PET, may help doctors look for cancer that has spread to the pelvis. Androgens are hormones that may cause the growth of prostate cancer cells. Apalutamide may help fight prostate cancer by blocking the use of androgens by the tumor cells. Metastasis-directed targeted radiation therapy uses high energy rays to kill tumor cells and shrink tumors that have spread. This trial may help doctors determine if using PET results to deliver more tailored treatment (i.e., adding apalutamide, with or without targeted radiation therapy, to standard of care treatment) works better than standard of care treatment alone in patients with biochemical recurrence of prostate cancer.
Recruiting
2 awards
Phase 3
Stereotactic Radiation + Immunotherapy
for Kidney Cancer
This phase II trial tests whether the addition of radiation to the primary tumor, typically given with stereotactic ablative radiation therapy (SABR), in combination with standard of care immunotherapy improves outcomes in patients with renal cell cancer that is not recommended for surgery and has spread from where it first started (primary site) to other places in the body (metastatic). Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses of radiation over a shorter period and cause less damage to normal tissue. Immunotherapy with monoclonal antibodies, such as nivolumab, ipilimumab, avelumab, and pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Axitinib, cabozantinib, and lenvatinib are in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving SABR in combination with standard of care immunotherapy may help shrink or stabilize the cancer in patients with renal cell cancer.
Recruiting
1 award
Phase 2
21 criteria
More about Scott M. Glaser
Clinical Trial Related
3 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Scott M. Glaser has experience with
- Aquaphor
- Miaderm
- Paclitaxel
- Radium-223 Dichloride
- Apalutamide
- Targeted Radiation Therapy
Breakdown of trials Scott M. Glaser has run
Ductal Carcinoma In Situ
Bone Metastasis
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Scott M. Glaser specialize in?
Scott M. Glaser focuses on Ductal Carcinoma In Situ and DCIS. In particular, much of their work with Ductal Carcinoma In Situ has involved treating patients, or patients who are undergoing treatment.
Is Scott M. Glaser currently recruiting for clinical trials?
Yes, Scott M. Glaser is currently recruiting for 2 clinical trials in Duarte California. If you're interested in participating, you should apply.
Are there any treatments that Scott M. Glaser has studied deeply?
Yes, Scott M. Glaser has studied treatments such as Aquaphor, Miaderm, Paclitaxel.
What is the best way to schedule an appointment with Scott M. Glaser?
Apply for one of the trials that Scott M. Glaser is conducting.
What is the office address of Scott M. Glaser?
The office of Scott M. Glaser is located at: City of Hope Comprehensive Cancer Center, Duarte, California 91010 United States. This is the address for their practice at the City of Hope Comprehensive Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.